Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Political Bargaining Intensifies Before Vote On EMA’s New Home

Executive Summary

In the run-up to Monday’s vote on the EMA’s future home, political horse-trading and vote-swapping behind the scenes makes it difficult to predict which EU city will win the prized agency.

You may also be interested in...



EMA Discloses Staff’s Preferred Host Cities, Amid Fears Relocation Could Batter Its Budget

The EMA has published its analysis of the 19 bids to host the agency post-Brexit, which confirms reports that five cities – Amsterdam, Barcelona, Copenhagen, Milan and Vienna – would bring the best result in terms of retaining staff when it relocates. The agency has expressed concern that low retention rates could hit operations and result in lower fee income, requiring an injection of cash from the EU budget.

EMA Paints Nightmare Scenario Of EU System ‘Unraveling’ If Relocation Goes Wrong

The European Medicines Agency says it could lose more than 70% of its staff if it moves to one of the cities least favored by current employees. In the worst-case scenario, the EMA says it would be unable to operate and that the regulatory system would “unravel.”

Rerouting Drug Supplies ‘A Priority’ After Brexit Transition Ends

Pharmaceutical companies in the UK have again been asked to ensure they have contingency measures in place to deal with potential supply problems at channel ports – this time in preparation for the UK’s formal departure from the EU’s single market and customs union at the beginning of 2021. The industry is continuing to push for a mutual recognition agreement on drug regulation.

Topics

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel